EUCTR2016-001160-11-Outside-EU/EEA
Active, not recruiting
Phase 1
An Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Tacrolimus Ointment in the Treatment of Atopic Dermatitis in Pediatric Patients
DrugsProtopic
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- F. Hoffmann-La Roche AG
- Enrollment
- 170
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Children 2\-10 years of age;
- •\- Mild to severe atopic dermatitis.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 170
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\- Skin disorder other than atopic dermatitis;
- •\- Previous treatment with tacrolimus ointment in a clinical study;
- •\- Known diagnosis or history of cancer, including skin cancer, or human immunodeficiency virus (HIV);
- •\- Clinically infected atopic dermatitis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCchronic hepatitis C (CHC) virus infection genotype 2 or 3 who responded during (i.e. had HCV-RNA < 50 IU/mL at the end of previous therapy), but relapsed after (i.e. had detectable HCV-RNA after the end of prior treatment) previous therapy with pegylated interferon and ribavirin given for at least 12 weeks and at most 24 weeks.EUCTR2006-003409-18-SESahlgrenska University Hospital, Östra100
Active, not recruiting
Not Applicable
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCchronic hepatitis C (CHC) virus infection genotype 2 or 3 who responded during (i.e. had HCV-RNA < 50 IU/mL at the end of previous therapy), but relapsed after (i.e. had detectable HCV-RNA after the end of prior treatment) previous therapy with pegylated interferon and ribavirin given for at least 12 weeks and at most 24 weeks.MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2006-003409-18-FIHUS100
Active, not recruiting
Phase 1
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCChronic hepatitis C (CHC) genotype 2 or 3 infection with previous response relapseEUCTR2006-003409-18-DKRelap-C study Steering Commitee100
Active, not recruiting
Phase 1
A Study to evaluate the effect and safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis CCompensated Cirrhosis and Non-cirrhoticsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2015-005577-20-PLAbbVie Deutschland GmbH & Co. KG160
Active, not recruiting
Phase 1
A Study to evaluate the effect and safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)EUCTR2015-005577-20-DEAbbVie Deutschland GmbH & Co. KG160